

Patient Name : Demo Patient Name
Age / Sex : 54 Y / F
Referred By : DEMO HOSPITAL
Centre : HOD Head Office

Lab No : Demo Visit No
Registration On : 21-Jan-25 11:15
Patient ID : UHID.DEMO.001

Anti Nuclear Antibody by IFA

Serum Sample

Accession No: DEMO_BARCODE **Collected On:** 21-Jan-25 11:15 **Received On:** 21-Jan-25 16:10 **Approved On:** 22-Jan-25 16:03

Observation	Result	Unit	Biological Ref. Interval	Method
ANA by IF	Positive			Immunofluorescence Microscopy
Primary Dilution	1:80			Immunofluorescence Microscopy
Primary Intensity on IF	1+			Immunofluorescence Microscopy
ANA Pattern	AC-1 Nuclear homogeneous			Immunofluorescence Microscopy
End Point Titre	1:80			Immunofluorescence Microscopy

Test Method:

ANTI-NUCLEAR AB-IFA, HEP2, SERUM - The Immunofluorescence assay is the Gold standard method for ANA testing. A negative ANA test virtually rules out a diagnosis of Systemic Lupus Erythematosus but a positive test may be indicative of a number of autoimmune connective tissue diseases such as Scleroderma, Rheumatoid Arthritis and Sjogren's syndrome. When correlated with the Clinical history & physical examination, it identifies almost all pts. With SLE (Sensitivity < 95%). Population studies show positive ANA in approximately 1-5% of healthy subjects. False positive results for ANA can be seen in pts. Taking certain medications like- hydralazine, isoniazid, procainamide etc. ANA test carried out by Immunofluorescence assay using HEP-2 slide (Tissue culture substrate) is more sensitive and specific than ANA carried out by enzyme immunoassay.

Titre:

ANA positivity of greater than or equal to 1:160 titre is of clinical significance in diagnosis of Collagen Vascular Disorders. Up to 40% of elderly subjects with chronic non-rheumatological illness have ANA positivity usually at low titre (1:40- 1:160)

Pattern:

The ANA pattern seen on Immunofluorescence staining helps in determination of the antibody specificities which need to be confirmed by Immunoblot techniques.

1+ Positivity = Minimum Immunofluorescence (IF) of no significance.

2+ Positivity = Mildly positive, clinically insignificant.

3+ Positivity = Significant positive, needs clinical correlation.

4+ Positivity = Strong positive, highly suggestive of collagen vascular disease. A titre estimation helps to monitor response to treatment,-----

Clinical Significance:

Location	Pattern	Target Antigen	Clinical Association
Nucleus	Homogeneous	Double strand DNA Histones Nucleosome, RNA, Single Strand DNA	SLE Drug Induced Lupus, SLE, RA SLE, MCTD, RA, PM, DM, SS
	Speckled	Sm U1-snRNP SSA/Ro SSB/La Ku Cyclin1(PCNA) Mitotin/Cyclin II	SLE MCTD, SLE, RA, sharp syndrome Sjogren's syndromes (SS)/SLE/Neonatal Lupus PM/DM/SLE/SS SLE/Overlap Syndromes DM
	Dense Fine Speckled (DFS)	Lens epithelium-derived growth factor (LEDGF), DNA binding transcription coactivator p75. (DFS-70)	Healthy individuals, Various inflammatory conditions like atopic dermatitis, interstitial cystitis, Asthma.
	Centromeres	Proteins of Kinetochore	sCREST syndrome,
	Nuclear Dots	Sp-100, NDP53	PBC, Rheumatic Disease
	Nuclear Membrane	Lamins, gp210, p62	CFS, Collagenases, PBC, AIH
Nucleolus	Nucleolar homogeneous	PM-Scl Scl-70	PM, DM, PSS(Diffuse) PSS(Diffuse)
	Nucleolar speckled	RNA-Polymerase I / NOR-90	Progressive Systemic Sclerosis(Diffuse)
	Nucleolar Pattern	Progressive Systemic Sclerosis(Diffuse)	Progressive Systemic Sclerosis(Diffuse)
Cytoplasm	Cytoplasmic speckled	Mitochondrial Lysosomal Golgi Complex Ribosome P Jo-1 SRP, PL12, TIF1-Gamma	PBC, Unknown SS/SLE/RA SLE Polymyositis (PM), PM/ DM, Myositis
	Cytoplasmic filament	F-Actin Vimentin Tropomyosin Cytoplasmic Rings & rods	AIH Unknown Unknown HCV Infection- on therapy
Cell Cycle (Mitotic Cells)	Centriole Mid Body Spindle Fibers		Unknown Rheumatic Disease

Please correlate results clinically.



This is a Demo Signature
and the doctor's signature should appear here

In case of any unexpected or alarming results, please contact us immediately for re-confirmation, clarifications, and rectifications, if needed.



There may be an additional PDF attachment in this report which has been redacted for privacy.
Please contact info@hod.care, if you would like to make a booking for this test.